ADMP - Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

• Adamis Pharmaceuticals ( NASDAQ: ADMP ) on Friday said the next meeting of a data safety board to review interim results from the company's ongoing phase 2/3 trial of its potential COVID-19 treatment had been set for late Sept.
• ADMP in the mid-to-late stage trial is evaluating the safety and efficacy of its nitroxide Tempol in COVID patients early in the infection.
• The Data Safety Monitoring Board (DSMB) had previously met to analyze interim data from the trial in March and June , and both times had recommended that the study continue without any changes.
• “With more than 200 patients enrolled, we believe this next DSMB data review could provide important additional insights into the safety and treatment effects of Tempol, as well as the future clinical path for Tempol,” said ADMP CEO David Marguglio.
• Adamis ( ADMP ) stock +1% to $0.37 in early trading.

For further details see: